RBM39 and glioblastoma: The data showed that in nine tumours, including BRCA, GBM, CHOL, OV, SKCM, THCA, THYM, UCEC and UVM, RBM39 expression negatively correlates with immune‐related functions such as neutrophil degranulation and chemokine transduction (Figure 7A–I).